Left Ventricular Hypertrophy Regression and Allopurinol More Questions Than Answers∗ by Reichek, Nathaniel
Journal of the American College of Cardiology Vol. 62, No. 24, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.08.695EDITORIAL COMMENT
Left Ventricular Hypertrophy
Regression and Allopurinol
More Questions Than Answers*
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In this issue of the Journal, Szwejkowski et al. (1), from the
University of Dundee, report that administration of allopu-
rinol, 600 mg daily for 9 months, was associated with
a reduction in magnetic resonance left ventricular (LV) mass
index that was statistically signiﬁcant compared with placebo
in type 2 diabetic patients with echocardiographic left
ventricular hypertrophy (LVH). While 90% of subjects had
been treated for hypertension, there was no change in blood
pressure that might provide an alternative potential mecha-
nism (1). The rationale for the trial was strong basic scientiﬁc
evidence that: 1) reactive oxygen species are important
mediators of myocardial remodeling, myocyte hypertrophy,
and myocardial ﬁbrosis; 2) xanthine oxidase produces such
superoxides and increases in cardiac remodeling; and 3)
xanthine oxidase inhibitors, such as allopurinol, reduce LV
remodeling in animal models (2–5). In addition, the Dundee
group has previously reported that allopurinol reduces LV
mass in patients with chronic kidney disease and in those
with ischemic heart disease (6,7). The authors point to the
association between LVH regression and reduced adverse
outcomes in the LIFE (Losartan Intervention For Endpoint
Reduction in Hypertension) study (8) as a basis for antici-
pation of potential improvements in cardiovascular outcomes
with administration of allopurinol in type 2 diabetes.See page 2284Compelling demonstrations of the value of LVH regres-
sion in risk reduction, primarily in hypertension, have been
a long time coming, although the belief that this would occur
has been prevalent for many years. It has been 44 years since
Kannel et al. (9) reported from Framingham that electro-
cardiographic evidence of LVH was associated with very
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of LV mass, and 34 years since the earliest demonstrations of
LVH regression during treatment of hypertension (11).
However, it took until 2004 for the echocardiographic
substudy of the LIFE study, led by Devereux et al. (8)
and Lindholm et al. (12), to demonstrate convincingly the
quantitative relationship of LV mass reduction to outcomes.
For much of that interval, the belief in the value of LVH
regression in hypertension was widespread, and even ubiq-
uitous, but the evidence was weak.
A novel strategy to prevent LVH and adverse remodel-
ing or to promote LVH regression is certainly of great
interest and would be highly relevant to large populations
with common highly-morbid cardiac disease states, in-
cluding myocardial infarction. Because diabetic patients
have a much higher prevalence of LVH than nondiabetics,
with or without hypertension, and diabetics have a much
higher prevalence of hypertension than nondiabetics, and
LVH reduction resulting from treatment of hypertension
is blunted in diabetics, this particular application of the
approach is especially attractive (13–15).
Unfortunately, the present study leaves many uncer-
tainties. First, the magnitude of the reduction in LV mass
index observed was very small, only 1.3 g/m2, and similar
small reductions in LV mass were reported in previous
studies of chronic renal disease by this group and in patients
with prior myocardial infarctions. In contrast, LVH regres-
sion in hypertension trials typically ranges from 5 to 10 g/m2
or more in the ﬁrst year and was 14 g/m2 in the LIFE study,
more than 10-fold greater than that reported in this study.
Whether such small changes in LV mass, even if increased in
later years, can alter the natural history of disease is certainly
unknown.
Second, in recent years there has been rapid growth of
understanding that the composition of hypertrophied myo-
cardium varies substantially, both among individuals with the
same disease and between disease states, and that differences
in composition affect prognosis and outcomes. The conse-
quence is that it is no longer sufﬁcient to evaluate simply the
amount of LV myocardium. Rather, one needs to specify
the components of the tissue and their change over time.
In most disorders, the main issue is myocardial ﬁbrosis.
Development of this theme has been driven by CMR, ﬁrst
with the development of methods for accurate quantitation
of macroscopic replacement ﬁbrosis in patients with myo-
cardial infarction, hypertrophic cardiomyopathy, nonis-
chemic dilated cardiomyopathy, and aortic stenosis (16–19).
More recently, there is convincing evidence that magnetic
resonance imaging T1 relaxation mapping of myocardium
before and after administration of gadolinium chelate
permits quantitation of microscopic interstitial ﬁbrosis,
which cannot be seen on images, and that this quantitation,
expressed as extracellular volume, correlates with histopa-
thology and impacts prognosis (20,21). Moreover, expan-
sion of extracellular volume in asymptomatic diabetics
is predictive of adverse cardiovascular outcomes (22).
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2295However, in diabetics, myocardial composition may differ
signiﬁcantly from that in other disorders because diabetic
patients may have very large amounts of advanced glyco-
sylation end (AGE) products in both intramyocardial
vasculature and in the myocardial interstitium, where they
may stiffen structural proteins such as collagen by cross-
linking and stimulate AGE receptors, leading to further
proﬁbrotic and inﬂammatory responses and altering myo-
cyte function (23). A number of preliminary reports suggest
that various blockers of AGE receptors or breakers of
glycosylation bonds may be effective in preventing or
reversing adverse AGE-related changes in cardiac tissues
(24,25). Thus, in diabetic patients, further quantitation
of composition of an expanded myocardial interstitium
may be needed and, hopefully, new noninvasive tools to
assess such composition. Surely it matters whether the
small LV mass index reduction is the result of reduction
in myocyte size or numbers, collagen content, or reduced
AGE. If only myocyte size or numbers were reduced, the
effect could actually be adverse. In any event, xanthine
oxidase inhibition is not the only potential new strategy
for improving cardiovascular outcomes in diabetics.
The ﬁnal worrisome feature of the data presented in this
study is the marked discrepancy between echocardiographic
estimates of LV mass at intake and the initial CMR LV
mass values. A difference between the two is expected and is
attributable to technical issues. On one hand, echo cardio-
graphic (echo) LV mass is calibrated against actual anatomic
pathology data, using a regression equation. On the other
hand, CMR methods commonly include protuberant
trabeculae of myocardium in the cavity volume. The pa-
pillary muscles, which tend to increase in size dispropor-
tionately in LVH, are also often included in the cavity
volume. Thus, it is expected that echocardiographic LV
mass will be higher than CMR LV mass in each subject and
closer to the true physical weight of the ventricle. However,
because CMR LV mass is considerably more reproducible
than echo LV mass, it remains the preferred approach
because it is both more sensitive and more speciﬁc for
changes over time. Further improvements in automated
segmentation of CMR images may well eliminate this issue.
However, in the present paper, the echo LV mass/CMR
LV mass ratio is far higher than usual in the literature,
resulting in some residual concern about interpretation of
the data.
Overall, then, the present study is a small step forward.
The results are tantalizing and must be pursued with
larger, longer randomized trials, powered to assess out-
comes and using all the CMR tools that shed light on
myocardial composition. It would also be extremely valu-
able to develop and apply molecular imaging agents tar-
geted to AGE in the myocardial interstitium, a task
probably best done with radionuclide imaging. Whatever
the ultimate outcome, one hopes it will not take as long to
clarify the role of xanthine oxidase inhibition in cardiacdisease as it has to characterize the beneﬁts of LVH
regression in systemic hypertension. In the interim, the
most one can conclude is the old Scottish legal verdict,
“not proven.”
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